AVENUE THERAPEUTICS INC (ATXI) Stock Price, Quote, News and Overview
NASDAQ:ATXI - Nasdaq - US05360L4032 - Common Stock - Currency: USD
ATXI Quote, Performance and Key Statistics
0.42
-0.43 (-50.71%)
The current stock price of ATXI is 0.42 USD. In the past month the price decreased by -69.78%. In the past year, price decreased by -96.3%.
ATXI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 53.38 | 696.37B | ||
| JNJ | JOHNSON & JOHNSON | 15.35 | 371.06B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.9 | 291.96B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.08 | 214.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.16 | 209.49B | ||
| MRK | MERCK & CO. INC. | 9.75 | 191.17B | ||
| PFE | PFIZER INC | 6.94 | 126.36B | ||
| SNY | SANOFI-ADR | 13.1 | 122.16B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.33 | 94.53B | ||
| GSK | GSK PLC-SPON ADR | 6.72 | 74.10B | ||
| ZTS | ZOETIS INC | 26.46 | 71.04B | ||
| HLN | HALEON PLC-ADR | 22.38 | 48.43B |
Related stock screener links
About ATXI
Company Profile
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 3 full-time employees. The company went IPO on 2017-06-27. The firm is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
Company Info
AVENUE THERAPEUTICS INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10036 US
CEO: Lucy Lu
Employees: 3
Phone: 17816524500
AVENUE THERAPEUTICS INC / ATXI FAQ
What is the stock price of AVENUE THERAPEUTICS INC today?
The current stock price of ATXI is 0.42 USD. The price decreased by -50.71% in the last trading session.
What is the ticker symbol for AVENUE THERAPEUTICS INC stock?
The exchange symbol of AVENUE THERAPEUTICS INC is ATXI and it is listed on the Nasdaq exchange.
On which exchange is ATXI stock listed?
ATXI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVENUE THERAPEUTICS INC stock?
7 analysts have analysed ATXI and the average price target is 8.16 USD. This implies a price increase of 1842.86% is expected in the next year compared to the current price of 0.42. Check the AVENUE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVENUE THERAPEUTICS INC worth?
AVENUE THERAPEUTICS INC (ATXI) has a market capitalization of 802.20K USD. This makes ATXI a Nano Cap stock.
How many employees does AVENUE THERAPEUTICS INC have?
AVENUE THERAPEUTICS INC (ATXI) currently has 3 employees.
Should I buy AVENUE THERAPEUTICS INC (ATXI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATXI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATXI, evaluating the profitability, health, valuation and growth aspects
- AVENUE THERAPEUTICS INC (ATXI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVENUE THERAPEUTICS INC (ATXI) Sales and EPS estimates to see what analysts future expectations are.
- AVENUE THERAPEUTICS INC (ATXI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVENUE THERAPEUTICS INC (ATXI) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVENUE THERAPEUTICS INC (ATXI) Stock Chart to make your own analysis
- AVENUE THERAPEUTICS INC (ATXI) Latest news and press-releases to stay up to date.
Does AVENUE THERAPEUTICS INC (ATXI) stock pay dividends?
ATXI does not pay a dividend.
When does AVENUE THERAPEUTICS INC (ATXI) report earnings?
AVENUE THERAPEUTICS INC (ATXI) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of AVENUE THERAPEUTICS INC (ATXI)?
AVENUE THERAPEUTICS INC (ATXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.25).
What is the Short Interest ratio of AVENUE THERAPEUTICS INC (ATXI) stock?
The outstanding short interest for AVENUE THERAPEUTICS INC (ATXI) is 5.02% of its float. Check the ownership tab for more information on the ATXI short interest.
ATXI Technical Analysis
ATXI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATXI. While ATXI seems to be doing ok healthwise, there are quite some concerns on its profitability.
ATXI Financial Highlights
Over the last trailing twelve months ATXI reported a non-GAAP Earnings per Share(EPS) of -19.25. The EPS increased by 83.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -360.69% | ||
| ROE | -362.76% | ||
| Debt/Equity | 0 |
ATXI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ATXI. The Buy consensus is the average rating of analysts ratings from 7 analysts.